🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#SoundOn 📣. It’s impossible to be still, especially when we have the power to transform lives. See how we go from #SciencetoMedicine.

#Breaking: The FDA has approved our novel anti-viral #antibody medicine for Zaire ebolavirus in adult and pediatric patients. #Ebola Read the full announcement: bit.ly/3nSzCrR

Announcing positive data from 524 additional non-hospitalized #COVID19 patients in ongoing P2/3 study of Regeneron’s investigational antibody cocktail: bit.ly/3mw6BRl

The FDA has issued an Emergency Use Authorization for our investigational antibody cocktail to treat mild to moderate #COVID19 in certain high-risk patients 12 years and older. Learn more: bit.ly/3lUkZ6e

Great place to do science!

Announcing with @Sanofi, the FDA has granted full approval to our #immunotherapy for patients with locally advanced #BasalCell Carcinoma (#BCC) and accelerated approval for patients with metastatic #BCC. Learn more: bit.ly/2MPuYgO

Today the FDA approved a first-of-its-kind treatment for people with #HoFH, an ultra #rare inherited form of high cholesterol. Read the full announcement: bit.ly/2OvpA2U

With @Sanofi, we are announcing the FDA approval of our #immunotherapy in first-line advanced #NonSmallCellLungCancer (#NSCLC) with ≥50% PD-L1 expression. Learn more: bit.ly/3dyViqs

We announced new data on our investigational medicine for patients with #cat allergy and mild asthma at #AAAAI21. Learn more: bit.ly/3qWbLc5

We're looking for a computational immunologist. Come join us! careers.regeneron.com/6gQLWZC

Today, the FDA accepted for review our sBLA for a treatment for children aged 6 to 11 years with moderate-to-severe #asthma. Learn more: bit.ly/3kLkyeH Sanofi

Announcing our Phase 3 trial in advanced #CervicalCancer was stopped early after achieving its primary efficacy endpoint. Today’s milestone is a “first” for the cervical cancer community. Learn why: bit.ly/3rOhtNN CC: Sanofi

More #COVID19 News: Positive results from a Phase 3 trial in recently infected asymptomatic patients demonstrate the ability of our investigational antibody cocktail to reduce progression to symptomatic #COVID19. Learn more: bit.ly/3t6f01H

Out now in Cell Reports: Potent neutralization of #SARSCoV2 variants of concern (including #Delta) by an #antibody with an uncommon genetic signature and structural mode of spike recognition cell.com/cell-reports/f…

Congrats Ivelin Georgiev, Ph.D. Kevin Kramer Andrea Shiakolas, PhD and all

Great place to do science!

#LIBRAseq with ligand blocking enables targeted discovery of functional (not just binding) #antibodies. Double #ACE2-blockers for both #SARSCoV2 and #SARSCoV were also identified. Easily generalizable for #mAb discovery aiming to block other types of antigen-ligand interactions

High-throughput discovery of #epitope-specific #antibodies? There's a #LIBRAseq for that. Great collaborative effort led by Lauren Walker. High-Throughput B Cell Epitope Determination by Next-Generation Sequencing frontiersin.org/article/10.338…

TRAPnSeq allows high-throughput profiling of antigen-specific antibody-secreting cells dlvr.it/SrrW3Y